Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: HardToFind who wrote (10045)	4/9/2018 1:10:41 PM
From: old 'n cranky	Read Replies (1) \| Respond to of 12873

Interesting. This is WAY less than I would expect a full set of clinical trials to cost, but my experience is VERY limited: "My guess is that it would cost on the order of $4 million of direct costs for each drug the company takes through human trials and submits for approval."

To: HardToFind who wrote (10045)	4/9/2018 1:27:17 PM
From: drkaz	Respond to of 12873

That was my understanding as well. I've been told that of the two candidates shown at the poster session a while back, one of them is easier to manufacture and one of them is slightly more effective. As our countdown clock to needing to raise capital is ticking down - if the difference in efficacy is minimal between the two, then I would recommend going for the one that is slightly easier to make. They can always go back and make "Herpescide vII" at a later date and then just market it as a improved product a year or two later.